Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1804-1813
DOI: 10.2967/jnumed.126.272007 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 20.08.2026. Verfasst von Jialin Xiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and …. Hauptthemen laut MEDLINE: Adenocarcinoma, Integrin alphaVbeta3, Gelatinases, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zitieren
APA
Xiang, J., Wen, X., Wang, R., Wang, J., Peng, X., Wang, Y., Liang, N., Cao, D., Chen, X., Zhu, Z., & Zhang, J. (2026). Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas. Journal of Nuclear Medicine, 67(11), 1804-1813. https://doi.org/10.2967/jnumed.126.272007
Vancouver
Xiang J, Wen X, Wang R, Wang J, Peng X, Wang Y, et al. Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas. Journal of Nuclear Medicine. 2026;67(11):1804-1813. doi:10.2967/jnumed.126.272007
BibTeX
@article{Xiang2026,
author = {Xiang, Jialin and Wen, Xuejun and Wang, Rongxi and Wang, Jiarou and Peng, Xingtong and Wang, Yanwei and Liang, Naixin and Cao, Dongyan and Chen, Xiaoyuan and Zhu, Zhaohui and Zhang, Jingjing},
title = {Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1804--1813},
doi = {10.2967/jnumed.126.272007}
}
EUVIMED